Phaseline

Targets › ALK1

ALK1 (Activin receptor type-1-like): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.

Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. (UniProt, P37023)

Open in Phaseline: the race on ALK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Diagonal TherapeuticsDIAG723
Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII
ALK1, BMPR2Phase 1Hereditary Hemorrhagic TelangiectasiaNov 2027

Conditions

Hereditary Hemorrhagic Telangiectasia (1)

Modalities

protein or peptide (1)

Companies

Diagonal Therapeutics (1)

Related targets

BMPR2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.